Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.
Press releases published on June 18, 2025
Troilus s’entend sur les modalités commerciales d’approvisionnement avec Aurubis pour son concentré de cuivre-or
GlobeNewswire
·
June 18, 2025
MONTRÉAL, 18 juin 2025 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (« Troilus » ou la « Société ») (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) a le plaisir d’annoncer qu’elle s’est entendue sur des modalités commerciales indicatives d’approvisionnement avec Aurubis AG …
Resultados operativos sólidos de la instalación de litio fortalecen la preparación comercial de la extracción directa de litio (DLE) de Summit Nanotech
GlobeNewswire
·
June 18, 2025
DENVER, June 18, 2025 (GLOBE NEWSWIRE) -- Summit Nanotech Corporation ("Summit") se enorgullece en anunciar el primer aniversario de operaciones de su sistema de extracción directa de litio (DLE) en EE. UU., que integra columnas de altura comercial y un …
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
GlobeNewswire
·
June 18, 2025
BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first …
Adant and QuantalRF Partner to Advance Antenna Performance in Wi-Fi Access Points
GlobeNewswire
·
June 18, 2025
PLEASANTON, Calif. and ZURICH, June 18, 2025 (GLOBE NEWSWIRE) -- Adant Technologies Inc., a global leader in smart antenna solutions for wireless connectivity, today announced a strategic partnership with QuantalRF, the pioneering developer of RF …
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
GlobeNewswire
·
June 18, 2025
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “ …
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
GlobeNewswire
·
June 18, 2025
Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2, 2025 ROCKVILLE, Md., June 18, 2025 ( …
Climb Channel Solutions Announces North American Alliance with Bugcrowd
GlobeNewswire
·
June 18, 2025
EATONTOWN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is pleased to announce a new North American …
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
GlobeNewswire
·
June 18, 2025
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch Nutriband is partnering with Kindeva to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ …
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
GlobeNewswire
·
June 18, 2025
WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, today announced …
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
GlobeNewswire
·
June 18, 2025
Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is …
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
GlobeNewswire
·
June 18, 2025
Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of …
Gogo successfully completes first 5G end-to-end call.
GlobeNewswire
·
June 18, 2025
Broomfield, CO., June 18, 2025 (GLOBE NEWSWIRE) -- Broomfield, CO./ June 18, 2025 – Gogo (NASDAQ: GOGO) confirms today that GCT Semiconductor has successfully completed the very first end-to-end call using its next-generation 5G technology. The call, which …
Extensive Greenland Lithium Exploration Campaign Launched by Brunswick Exploration
GlobeNewswire
·
June 18, 2025
MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce it has launched an aggressive regional-scale prospecting and mapping initiative on its sizeable …
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
GlobeNewswire
·
June 18, 2025
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of …
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
GlobeNewswire
·
June 18, 2025
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases …
HydroGraph Announces Kjirstin Breure as Board Chair
GlobeNewswire
·
June 18, 2025
VANCOUVER, British Columbia, June 18, 2025 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (the “Company” or “HydroGraph”) a leading producer of ultra-pure graphene and advanced nanomaterials, today announced the selection of …
A.I.S. Resources Closes Shares for Debt Transaction
GlobeNewswire
·
June 18, 2025
VANCOUVER, British Columbia, June 18, 2025 (GLOBE NEWSWIRE) -- A.I.S. Resources Limited (TSXV: AIS, OTC- PINK: AISSF) (“AIS” or the “Company”) announces that further to the Company’s press release dated February 24, 2025 the Company has settled $380,927.75 …
NexGold VP Sustainability Receives Prestigious Mining Society of Nova Scotia Medal
GlobeNewswire
·
June 18, 2025
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that Deidre Puddister, VP Sustainability with NexGold, has been honoured with the prestigious Mining Society of …
BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency
GlobeNewswire
·
June 18, 2025
BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 from the FDA regarding the development of BPM31510 for PCQD …
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
GlobeNewswire
·
June 18, 2025
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I …